Arcus Biosciences Target Price

Where could RCUS trade next? Consensus target price: $39.

Get informed when a big investor buys or sells

+ Follow

Share Price

$19.3

Average Target Price

$39.00

102.1% upside

6 analysts in the last 4 months

High: $45 | Low: $23

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

Date	Analyst	Price Target	Current Upside/Downside
2026-10-21	Truist FinancialSupawat Thongthip	$41	112.4% upside
2026-09-08	Truist Financial	$40	107.3% upside
2026-08-10	Morgan Stanley	$23	19.2% upside
2026-08-07	Goldman SachsRichard Law	$42	117.6% upside
2026-08-06	Wedbush	$43	122.8% upside
2026-07-20	H.C. WainwrightEmily Bodnar	$45	133.2% upside
2026-05-18	Truist Financial	$35	81.3% upside
2026-05-11	Morgan Stanley	$22	14% upside
2026-04-20	Leerink Partners	$47	143.5% upside
2026-02-12	Wells Fargo	$23	19.2% upside
2026-01-12	Goldman SachsRichard Law	$28	45.1% upside
2026-01-08	Morgan Stanley	$20	3.6% upside
2025-12-12	Truist Financial	$30	55.4% upside
2025-12-12	H.C. Wainwright	$32	65.8% upside
2025-10-30	Goldman SachsSalveen Richter	$16	17.1% downside
2025-10-29	Wedbush	$35	81.3% upside
2025-10-29	H.C. Wainwright	$28	45.1% upside
2025-10-07	Truist FinancialAsthika Goonewardene	$39	102.1% upside
2025-05-07	Wells FargoEva Fortea Verdejo	$26	34.7% upside
2024-10-24	CitigroupYigal Nochomovitz	$46	138.3% upside
2024-10-21	H.C. WainwrightEmily Bodnar	$20	3.6% upside
2024-10-08	Wells FargoEva Fortea Verdejo	$29	50.3% upside
2024-10-08	Morgan StanleyJudah Frommer	$35	81.3% upside
2024-08-09	Bank of America SecuritiesJason Zemansky	$23	19.2% upside
2024-07-08	BarclaysPeter Lawson	$25	29.5% upside
2024-06-24	Truist FinancialAsthika Goonewardene	$44	128% upside
2024-06-04	BarclaysPeter Lawson	$35	81.3% upside
2022-12-20	Citigroup	$42	117.6% upside
2022-11-23	Citigroup	$37	91.7% upside
2022-05-11	WedbushRobert Driscoll	$42	117.6% upside

Arcus Biosciences (RCUS) FAQ

The latest target price for RCUS is $39. Investors often review this figure alongside Arcus Biosciences's historical trend and sector peers before judging valuation or financial health.

Arcus Biosciences trades near $19.3 while the consensus target sits at $39 (102.1% upside). Targets are estimates based on earnings forecasts and valuation models; they change when analysts update ratings or revise models. Compare the average with the high and low targets for a fuller picture.

After noting RCUS's target price ($39), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Arcus Biosciences's target price against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.